TOKYO
R-Tech Ueno, Ltd. (JASDAQ:4573):
A resolution was passed during the Board of Directors’ Meeting held on February 12, 2014 to revise our dividend per share forecast as described below.
1. Reasons for the revisions made to the dividend forecast
We consider the return of profits to shareholders to be one of our important main issues. We will continue to deliver steady dividend distributions to our shareholders while considering future business performance.
In line with this policy and overall consideration of the current business performance and financial conditions, we have increased the expected dividend for the fiscal year ending March 2014 by 5 yen from 20 yen to 25 yen per share.
2. Revisions to the Dividend Forecast
|
(1) Dividend forecast for the fiscal year ending March 2014 |
||||||||||
|
|
Annual dividend | |||||||||
| End of 1st quarter | End of 2nd quarter | End of 3rd quarter | Year-end | Total | ||||||
| Yen | Yen | Yen | Yen | Yen | ||||||
| Previous forecast |
– |
– |
– |
20.00 | 20.00 | |||||
| Revised forecast |
– |
– |
– |
25.00 | 25.00 | |||||
| Actual results for the current fiscal year |
– |
– |
– |
|||||||
|
(Reference) |
– |
– |
– |
15.00 | 15.00 | |||||
| (Note) | We conducted a 200 for 1 stock split on July 1, 2013. Subsequently, we show the value of dividends for FY3/13 based upon an assumption that the stock split was performed at the start of the previous fiscal year. The dividend payment would be JPY3,000 per share if the effect of the stock split is excluded. | |
About R-Tech Ueno, Ltd.
R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.
We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and developing and selling pharmaceutical products through the eyes of doctors.” We are promoting the development of new drugs for unmet medical needs for which the government provides recommendations and assistance, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).
CONTACT
R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp
